(Public, NASDAQ:ICLR)   Watch this stock  
Find more results for NASDAQ: ICLR
-0.73 (-0.64%)
Oct 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 113.55 - 114.97
52 week 73.76 - 117.53
Open 114.66
Vol / Avg. 282,713.00/276,868.00
Mkt cap 6.14B
P/E 23.06
Div/yield     -
EPS 4.93
Shares 54.04M
Beta 0.63
Inst. own 102%
Nov 9, 2017
ICON PLC at Financial Times Global Pharmaceutical and Biotechnology Conference Add to calendar
Oct 26, 2017
Q3 2017 ICON PLC Earnings Call - 10:00AM EDT - Add to calendar
Oct 26, 2017
Q3 2017 ICON PLC Earnings Release Add to calendar
Sep 7, 2017
ICON PLC at Robert W Baird Gobal Healthcare Conference
Sep 6, 2017
ICON PLC at Wells Fargo Healthcare Conference
Jul 27, 2017
Q2 2017 ICON PLC Earnings Call - Webcast
Jul 27, 2017
Q2 2017 ICON PLC Earnings Release
Jul 25, 2017
ICON PLC Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin 15.04% 15.73%
Operating margin 18.10% 18.70%
EBITD margin - 22.77%
Return on average assets 13.83% 14.80%
Return on average equity 26.34% 30.70%
Employees 12,327 -
CDP Score - -


South County Business Park, Dublin 18
DUBLIN, 00000
+353-1-2912000 (Phone)
+353-1-2912700 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. Its services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. The Company's information systems offerings include ICONIK, Firecrest, ADDPLAN, AptivAdvantage and Aptiv Insite. It conducts various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial. The Company offers clinical development services, including investigator recruitment, patient registries, outcomes research, clinical data management, immunoassay development and others.

Officers and directors

Ciaran Murray Chairman of the Board
Age: 53
Bio & Compensation  - Reuters
Steve Cutler Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Brendan Brennan Chief Financial Officer
Age: 36
Bio & Compensation  - Reuters
Diarmaid Cunningham Executive Vice President, General Counsel, Secretary
Age: 40
Bio & Compensation  - Reuters
Hugh Brady Non-Executive Director
Age: 57
Bio & Compensation  - Reuters
John Climax Non-Executive Director
Age: 62
Bio & Compensation  - Reuters
William W. Hall M.D., Ph.D. Non-Executive Director
Age: 65
Bio & Compensation  - Reuters
Ronan Lambe Ph.D. Non-Executive Director
Age: 75
Bio & Compensation  - Reuters
Eugene McCague Non-Executive Director
Bio & Compensation  - Reuters